Ciladopa

Ciladopa
Clinical data
Other namesAY-27,110
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 2-{4-[(2S)-2-(3,4-dimethoxyphenyl)-2-hydroxyethyl]piperazin-1-yl}cyclohepta-2,4,6-trien-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H26N2O4
Molar mass370.449 g·mol−1
3D model (JSmol)
  • O=C3/C=C\C=C/C=C3/N2CCN(C[C@@H](O)c1ccc(OC)c(OC)c1)CC2

Ciladopa (developmental code name AY-27,110) is a dopamine agonist with a similar chemical structure to dopamine.[1] It was under investigation as an antiparkinsonian agent but was discontinued due to concerns of tumorogenesis in rodents.[2][3][4][5]

  1. ^ Voith K (1985). "The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats". Psychopharmacology. 85 (4): 405–9. doi:10.1007/BF00429654. PMID 3927334. S2CID 1573473.
  2. ^ Koller WC, Fields JZ, Gordon JH, Perlow MJ (September 1986). "Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug". Neuropharmacology. 25 (9): 973–9. doi:10.1016/0028-3908(86)90190-5. PMID 3774130. S2CID 19175441.
  3. ^ Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). "A double-blind evaluation of ciladopa in Parkinson's disease". Movement Disorders. 2 (3): 211–7. doi:10.1002/mds.870020308. PMID 3332914. S2CID 31784301.
  4. ^ Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (May 1987). "Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa". Neurology. 37 (5): 863–5. doi:10.1212/wnl.37.5.863. PMID 3574692. S2CID 25273606.
  5. ^ Lang AE (August 1987). "Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine"". The Canadian Journal of Neurological Sciences. 14 (3 Suppl): 474–82. doi:10.1017/s031716710003794x. PMID 3315148.